0
Preliminary Reports |

Inhalation of a Dry Powder Tobramycin PulmoSphere Formulation in Healthy Volunteers*

Michael T. Newhouse; Peter H. Hirst; Sarma P. Duddu; Yulia H. Walter; Thomas E. Tarara; Andrew R. Clark; Jeffry G. Weers
Author and Funding Information

*From Inhale Therapeutic Systems Inc. (Drs. Newhouse, Duddu, Clark, and Weers, Ms. Walter, and Mr. Tarara), San Carlos, CA; and Pharmaceutical Profiles, Ltd. (Dr. Hirst), Nottingham, UK.

Correspondence to: Jeffry G. Weers, PhD, Inhale Therapeutic Systems Inc., 150 Industrial Rd, San Carlos, CA 94070; e-mail: jweers@inhale.com



Chest. 2003;124(1):360-366. doi:10.1378/chest.124.1.360
Text Size: A A A
Published online

Study objectives: To evaluate the efficiency and reproducibility of pulmonary delivery of an investigational tobramycin PulmoSphere formulation (PStob) [Inhale Therapeutic Systems; San Carlos, CA] by a passive dry powder inhaler, and to compare serum concentrations and whole-lung deposition with a commercial nebulized tobramycin product (TOBI; Chiron Corporation; Seattle, WA).

Design: A five-period, open-label, nonrandomized crossover study.

Participants: Fourteen healthy volunteers were studied, and 12 completed the study.

Interventions: PStob powder was manufactured using lipid-based PulmoSphere technology, producing highly dispersible porous particles. PStob was radiolabeled with 99mTc, and in vitro experiments confirmed it as a valid drug marker. To identify whole-lung distribution via scintigraphy, subjects inhaled contents of a single capsule (72 L/min) containing 25 mg of 99mTc-labeled PStob (13.5 mg of tobramycin free base) in periods 1 to 3. In period 4, subjects received 99mTc nebulized tobramycin, approximately 2.5 mL of 300 mg/5 mL. Deposition and blood samples were obtained. In period 5, six 25-mg doses of unlabeled PStob (81 mg of tobramycin base) were inhaled and blood samples were collected.

Measurements and results: Mean whole-lung deposition of PStob was 34 ± 6% and nebulized tobramycin was 5 ± 2%. Peak tobramycin concentration in serum (Cmax) values were 0.6 μg/mL with PStob and 0.28 μg/mL after nebulized tobramycin. Serum area under the curve was 4.4 μg × h/mL vs 2.1 μg × h/mL for nebulized tobramycin. Median time to Cmax for PStob was comparable to nebulized tobramycin.

Conclusions: The aerosol doses of PStob (25 mg and 150 mg) were well dispersed and tolerated. Serum drug concentrations matched scintigraphy data and were roughly twice that of the comparator. Intrasubject dose variability for three equivalent periods did not exceed 18% relative SD. PStob Cmax (0.6 μg/mL) was well below the toxic threshold (2 μg/mL).

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543